Cardinal Health, Inc. (NYSE: CAH) is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 6.67%. CAH's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 12.91%. Q4 Estimates For the fiscal fourth quarter, the consensus mark for earnings is pegged at $1.72 per share, indicating an improvement of 10.9% from the prior-year quarter's reported figure. The same for revenues is pinned at $58.72 billion, implying growth of 9.9% year over year. Factors to Note From the fiscal third quarter of 2024, Cardinal Health started reporting its results under new operating segments — Pharmaceutical and Specialty solutions, Global Medical Products and Distribution (GMPD) segment, nuclear at-Home and OptiFreight. The third quarter of fiscal 2024 witnessed an uptick in revenues in the Pharmaceutical segment, which amounted to approximately $50.7 billion, up 9% on a year-over-year basis. The Pharmaceutical Distribution and Specialty Solutions segment's performance highlighted branded pharmaceutical sales growth from existing customers. The segment's profit increased 4% during the fiscal third quarter. This momentum is likely to have continued in the fiscal fourth quarter as well. Moreover, the rising demand for GLP-1 medications is likely to have acted as a tailwind. Higher contributions from brand and specialty products, as well as the effectiveness of the generics program, drove the positive outcome of the pharmaceutical segment ...